Skip to main content

Psoriatic arthritis

      RT @RichardPAConway: Guselkumab improves anaemia in PsA. Appears to correlate with CRP response, ie inflammatory effect.

      Richard Conway RichardPAConway

      3 years 10 months ago
      Guselkumab improves anaemia in PsA. Appears to correlate with CRP response, ie inflammatory effect. Anaemia resolution associated good outcomes, but many with good outcomes still anaemic. Abstr#1331 #ACR21 @RheumNow https://t.co/LL63Qc0nk5
      RT @swethaann23: Study on enthesitis response to biologic Rx

      ⭐️TNFI caused a 2❎ 🔽mean ActiveMASEI score compar

      swethaann23 swethaann23

      3 years 10 months ago
      Study on enthesitis response to biologic Rx ⭐️TNFI caused a 2❎ 🔽mean ActiveMASEI score compared to secukinumab ⭐️ 🔽PASI and DLQI score more in TNFI than Secukinumab 🔰Superiority of TNFi versus secukinumab in regards to active enthesitis Abst#1356 #ACR21 @Rheumnow https://t.co/wdzMYmn8AJ
      RT @RichardPAConway: Dr Elliott presenting on US assessment of enthesitis with TNFi vs secukinumab. Surprisingly TNFi sh

      Richard Conway RichardPAConway

      3 years 10 months ago
      Dr Elliott presenting on US assessment of enthesitis with TNFi vs secukinumab. Surprisingly TNFi showed a more marked decrease in US enthesitis. Abstr#1356 #ACR21 @RheumNow https://t.co/XXgYMgkMyP
      RT @RichardPAConway: Guselkumab (IL23p19 inhibitor) positive effect on axial outcomes in PsA, durable response across 2

      Richard Conway RichardPAConway

      3 years 10 months ago
      Guselkumab (IL23p19 inhibitor) positive effect on axial outcomes in PsA, durable response across 2 years. Abstr#1330 #ACR21 @RheumNow https://t.co/8LOSdzCvRc
      RT @synovialjoints: A meta-analysis of 5 cohort studies showed that PsA is significantly associated with vertebral fract

      Dr. Antoni Chan synovialjoints

      3 years 10 months ago
      A meta-analysis of 5 cohort studies showed that PsA is significantly associated with vertebral fractures pooled OR 2.09 (95% CI, 1.11 – 3.96; I2 70%). The review was not suggestive of publication bias @RheumNow #ACR21 Abst#1304 https://t.co/rjC776FXUA https://t.co/QvMWxN6ZZ7
      RT @RichardPAConway: Meta-analysis shows increased risk of vertebral fracture in PsA, OR 2.09. Abstr#1304 #ACR21 @RheumN

      Richard Conway RichardPAConway

      3 years 10 months ago
      Meta-analysis shows increased risk of vertebral fracture in PsA, OR 2.09. Abstr#1304 #ACR21 @RheumNow https://t.co/kTrR7I3HA0
      RT @swethaann23: Minimal disease activity achievement in PsA achieved by 22.8% in 6 mo of b/ts DMARD

      MDA achievers were

      swethaann23 swethaann23

      3 years 10 months ago
      Minimal disease activity achievement in PsA achieved by 22.8% in 6 mo of b/ts DMARD MDA achievers were: ➡️Younger ➡️🔽 Disease duration; ➡️ Male ➡️Non-obese ➡️bDMARD-naïve at baseline ➡️🔼 probability achieving MDA components➕MCID PROMs at 6 mo Abst# 1344 #ACR21 @Rheumnow
      RT @RichardPAConway: Effect of BMI on PRO treatment response in PsA. Increasing BMI associated with lower response. More

      Richard Conway RichardPAConway

      3 years 10 months ago
      Effect of BMI on PRO treatment response in PsA. Increasing BMI associated with lower response. More pronounced in TNFi than IL-17 or JAKi. Abstr#1327 #ACR21 @RheumNow https://t.co/qhgVlW72uM
      The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 2 (#ACRbest).
      RT @_Castillo_Pedro: AS and PsA: Mortality vs Gen Pop (meta-analysis)
      AS:
      👉⬆️All-cause
      👉⬆️CVD
      PsA:
      👉All

      Pedro Castillo _Castillo_Pedro

      3 years 10 months ago
      AS and PsA: Mortality vs Gen Pop (meta-analysis) AS: 👉⬆️All-cause 👉⬆️CVD PsA: 👉All-cause not higher 👉⬆️CVD, Respiratory, and Infectious etiologies Important to consider CVD and other comorbidities. https://t.co/9K4qNpYvMb #ACR21 Abst#0569 @RheumNow
      ×